BCAX NASDAQ
Bicara Therapeutics Inc. Common Stock
1W: +0.9%
1M: -11.8%
3M: +34.6%
YTD: +27.2%
1Y: +38.6%
$21.68
+0.84 (+4.03%)
Weekly Expected Move ±5.8%
$18
$19
$20
$21
$23
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (32)
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
Bicara (BCAX) Q1 2026 Earnings Transcript
Bicara plans Q3 alternative dosing study of ~150–200 patients as it targets mid-2027 interim analysis
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000
12 Health Care Stocks Moving In Wednesday's After-Market Session
Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade
Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year?
Bicara Therapeutics To Rally Around 121%? Here Are 10 Top Analyst Forecasts For Tuesday
Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy?
Bicara Therapeutics GAAP EPS of -$0.68
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Earnings Scheduled For March 30, 2026
Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder.
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Bleakley Financial Group LLC Makes New $481,000 Investment in Bicara Therapeutics Inc. $BCAX
Bicara Therapeutics Inc. (BCAX) Discusses Ficerafusp Alfa Clinical Data and Less Frequent Dosing in First-Line HPV-Negative Head and Neck Squamous Cell Carcinoma Transcript
Bicara Therapeutics prices offering to raise $150M
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
Bicara Therapeutics Announces Proposed Public Offering of Common Stock
Bicara Therapeutics to Participate in Upcoming Investor Conferences
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Ivan Hyep Sells 1,882 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock
Ryan Cohlhepp Sells 3,828 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12
Bicara Therapeutics' Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026
Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025
Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout